More recently, another research group confirmed that the TGF-β1 released by microglia/macrophages enhances the invasive capacity of the CD133+ glioma cells (glioma stem-like cells) more than the CD133− committed cells, and that this process most likely occurred through type II TGF-β receptor. The gene discussed is TGFB1; the disease is glioma.